论文部分内容阅读
用￣（１２５）Ｉ标记的表皮生长因子（￣（１２５）Ｉ－ＥＧＦ）作为配基，用标准的ＥＧＦ作为竞争剂，采用单点饱和分析法测定了３６例乳腺癌组织中的ＥＧＦＲ含量，范围在１～１２２ｆｍｏｌ／ｍｇ膜蛋白之间，以１０ｆｍｏｌ／ｍｇ膜蛋白以上为阳性，乳腺癌阳性率为３８％。按乳腺癌临床分期的结果表明，临床分期越高，阳性率也越高。有淋巴结转移者较无淋巴结转移的病人阳性率有增高趋势。证明表皮生长因子受体与乳腺癌的恶性程度有关，但癌各组织学类型之间阳性率未见差别。
Using ̄(125)I-labeled epidermal growth factor ( (125)I-EGF) as a ligand, using standard EGF as a competitor, the single-point saturation assay was used to determine the levels of EGFR in 36 breast cancer tissues. The range was between 1 and 122 fmol/mg of membrane protein, more than 10 fmol/mg of membrane protein was positive, and the positive rate of breast cancer was 38%. According to the clinical stage of breast cancer, the higher the clinical stage, the higher the positive rate. The positive rate of lymph node metastasis was higher than that of patients without lymph node metastasis. The epidermal growth factor receptor was shown to be related to the degree of malignancy of breast cancer, but no difference was found in the positive rate between the histological types of cancer.